Clover Health (NASDAQ:CLOV) posts better-than-expected sales in Q3 2026, full-year outlook slightly exceeds expectations
Clover Health (CLOV) reported Q3 2026 revenue of $759.3M, beating estimates by 2.6%. EPS was $0.01, and adjusted EBITDA was $16.05M, both exceeding expectations. The company raised its full-year revenue guidance to $2.99B. Operating and free cash flow margins improved year-over-year.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance could trigger buying interest, especially from investors seeking exposure to growing health‑tech.
Market read
First‑report earnings with beat and guidance lift; actionable for short‑term traders.
What to watch
Potential headwinds from regulatory changes in Medicare reimbursement.
Background
Clover Health is a Nasdaq‑listed health‑tech company focused on Medicare Advantage.
Ticker impact
Clover Health reported Q3 2026 revenue of $759.3M beating estimates and raised full-year revenue guidance to $2.99B.
likely upward pressure as the market prices in the beat and higher guidance
Both revenue and adjusted EBITDA exceeded consensus, and guidance was lifted, which typically supports a price rally.
Market effects
Improves outlook for the Medicare Advantage and health‑tech sector.
Positive for US fintech and health‑tech stocks.
Limited to U.S. markets.
Counterpoint
If guidance still falls short of analyst expectations for FY, the beat may be muted.
Key entities
- CompanyClover Health
NASDAQ‑listed health‑tech firm.
